Of the three, USP30 is being pursued for PD therapeutic development based on studies demonstrating the ability of USP30 KO to enhance mitophagy in cellular systems and rescue PD-like motor phenotypes in PINK1 and PRKN KO drosophila [59,60]. Here, PRKN is linked to Parkinson disease.